About: Influenza treatment with neuraminidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Influenza treatment with neuraminidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Influenza treatment with neuraminidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom
Creator	Sander, Beate Er, Fred Gic, Strate Hay Den, G Hoff Mann-, F Ing, Pric James, · Mann, Berge Mar, · Mark, Gyld Phar, Ltd Ra Mueller, Elvi Ris, Mor Rito, · Roche, La Vi, Di
Source	PMC
abstract	We assessed the cost-effectiveness and cost-utility of treating influenza with neuraminidase inhibitors (oseltamivir and zanamivir) from a health care payer’s and societal perspective in the United Kingdom. A simulation model was developed to predict morbidity and mortality due to influenza and its specified complications, comparing neuraminidase inhibitors with usual care in an otherwise healthy adult population. Robustness of the results was tested by one-way and multiway as well as probabilistic sensitivity analyses. Treatment with either neuraminidase inhibitor results in reduced morbidity and faster return to normal activities. However, oseltamivir dominates zanamivir in cost-utility analysis due to its lower costs. Comparing oseltamivir with usual care, the costs are £14.36 per day of normal activity gained and £5,600 per quality-adjusted life-year gained from the healthcare payer perspective. Oseltamivir dominates usual care from the societal perspective. Treatment with oseltamivir is a cost-effective strategy for otherwise healthy adults in the UK from both the healthcare payer and societal perspective.
has issue date	2005-09-17(xsd:dateTime)
bibo:doi	10.1007/s10198-005-0297-y
bibo:pmid	15875227
has license	no-cc
sha1sum (hex)	e9cbd7607bbe38068fba47fb43fa6b3d3f854dce
schema:url	https://doi.org/10.1007/s10198-005-0297-y
resource representing a document's title	Influenza treatment with neuraminidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom
has PubMed Central identifier	PMC7087894
has PubMed identifier	15875227
schema:publication	Eur J Health Econ
resource representing a document's body	covid:e9cbd7607bbe38068fba47fb43fa6b3d3f854dce#body_text
is schema:about of	named entity 'PEO' named entity 'AGED' named entity 'ADULTS' named entity 'MED' named entity 'LUTE' named entity 'CAL' named entity 'UNIT' named entity '5B1' named entity 'NOM' named entity 'GARD' named entity 'PHY' named entity 'TERMS' named entity 'FLU' named entity 'USE' named entity 'COM' named entity 'DIS' named entity 'ITS' named entity 'PUB' named entity 'NAL' named entity 'VISITS' named entity 'HOW' named entity 'EPI' named entity 'KING' named entity 'STUDY' named entity 'DER' named entity 'ECO' named entity 'MID' named entity 'KNOWN' named entity 'PLI' named entity 'DRUG USE' named entity 'FOUND' named entity 'DUR' named entity 'PLE' named entity 'CLIN' named entity 'NESS' named entity 'PIRA' named entity 'BUR' named entity 'RES' named entity 'GREATER' named entity 'GEN' named entity 'DOM' named entity 'CARE' named entity 'ABLING' named entity 'ILL' named entity 'RUS' named entity 'AWARE' named entity 'LIC' named entity 'CHIL' named entity 'TRI' named entity 'DEN' named entity 'CENT' named entity 'YEARS' named entity 'LAT' named entity 'SIZE' named entity 'avail' named entity 'ed King' named entity 'avail' named entity 'zanamivir' named entity 'zanamivir' named entity 'ison' named entity 'zanamivir' named entity 'NHS' named entity 'zanamivir' named entity 'zanamivir' named entity 'zanamivir' named entity 'zanamivir'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software